Suven Life Sciences Ltd
NSE:SUVEN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (85.4), the stock would be worth ₹-839.88 (486% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -22.1 | ₹217.33 |
0%
|
| Industry Average | 85.4 | ₹-839.88 |
-486%
|
| Country Average | 35.9 | ₹-353.16 |
-262%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Suven Life Sciences Ltd
NSE:SUVEN
|
49.4B INR | -22.1 | -18 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 1 841 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
178B USD | 31.8 | 26 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.6B USD | 26.2 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 105.4 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
331.7B CNY | 24.7 | 16.8 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.5B CHF | -165.5 | -119.8 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 34.5 | 25.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.3B USD | 56.9 | 47.2 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.9B USD | 18.9 | 19.8 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26B USD | 33 | 29.9 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 20.7 |
| Median | 35.9 |
| 70th Percentile | 64.8 |
| Max | 50 585.9 |
Other Multiples
Suven Life Sciences Ltd
Glance View
Suven Life Sciences Ltd. engages on discovering, developing, and commercializing novel pharmaceutical products which are used in classic therapies. The company is headquartered in Hyderabad, Telangana and currently employs 117 full-time employees. The firm is focused on discovering and developing new chemical entities (NCEs), which are central nervous system therapies for the treatment of cognitive disorders, depressive disorders, sleep disorders, psychiatric disorders, pain and inflammation, gastrointestinal motility disorders. Its research targets include serotonin 6 receptor, serotonin 4 receptor, histamine 3 receptor, Nicotinic acetylcholine (Alpha4beta2) receptor, muscarinic M1 receptor, muscarinic M4 receptor, multimodal and P2X purinoceptor 7 receptor. The company provides a range of Drug Discovery and Development Support Services (DDDSS). The firm offers research services specializing in synthetic, medicinal and analytical chemistry, in-vitro assay development and screening, drug metabolism and pharmacokinetics, toxicology and safety pharmacology, bioanalysis, and NCE formulations.
